振華股份(603067.SH):重慶民豐投建的硫酸裝置建成投產
格隆匯3月27日丨 振華股份(603067.SH)公佈,公司全資子公司重慶民豐化工有限責任公司(“重慶民豐”)投資建設的硫酸裝置已建設完成,於近日正式投產。
該硫酸裝置設計產能為30萬噸/年,其中包括3萬噸/年分析純級硫酸。目前,裝置運行穩定,產品品質達標,除了能夠滿足重慶民豐基地全年硫酸自用需求外,還將會有富餘產品對外銷售。
硫酸裝置在生產硫酸過程中副產的蒸汽,亦可用於發電,目前已實現酸、汽、電聯產,重慶民豐基地原有的燃煤鍋爐裝置已全部停用。
硫酸裝置順利投產,將使重慶民豐基地生產成本得到一定程度的優化;也是公司完善上游原材料佈局、實施鉻化學品全產業鏈一體化經營理念的重要環節。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.